skip to main content

Prurigo nodularis — SCE Dermatology MCQ

Instant feedback + full explanation. One question, done properly.

HardGeneral dermatology & dermatology in primary health carePrurigo nodularisSCE Dermatology

An NHS clinician is considering dupilumab for an adult with moderate-to-severe prurigo nodularis suitable for systemic therapy. Which commissioning statement reflects NICE TA955?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Dupilumab is not recommended for routine NHS use for this indication

Explanation lettering: E = shown as A · A = shown as B · B = shown as E

A is correct. NICE TA955 did not recommend dupilumab for routine NHS treatment of moderate-to-severe prurigo nodularis when systemic treatment is suitable. Clinical trials showed benefit, but the comparator did not adequately reflect NHS best supportive care and the economic estimates were uncertain and above the acceptable range. This is a commissioning conclusion, not evidence that the drug is biologically ineffective or never usable outside routine funding. Existing NHS treatment begun before guidance is protected by a continuation clause. The underlying causes of itch and individualized conventional options still require assessment.

Reference: NICE TA955: dupilumab for prurigo nodularis: https://www.nice.org.uk/guidance/ta955/chapter/1-Recommendations